ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Methadone for intractable cancer pain associated with pelvic floor lesions: a retrospective analysis of 36 cases.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to examine the efficacy and safety of methadone for refractory cancer pain caused by pelvic floor lesions.
methodsBetween April 2016 and September 2023, we retrospectively investigated all cases in which methadone was administered by our Palliative Care Team for refractory cancer pain due to pelvic floor lesions, based on the electronic medical records.
resultsThe extracted cases totaled 36 (21 females), and the age was 55.1 ± 15.1 years. The primary sites of malignancy were rectum, colon, and uterine cervix, each of which accounted for nine cases, and others in nine. The causes of refractory pain included pelvic tumors in 36, sacral metastasis/infiltration in 7, and others in 11 (with some overlaps). The prior opioid dosage (oral morphine equivalent) (median, (IQR)) was 168.0 (95.3, 352.5) mg/day. The starting, maximum, and final doses of methadone were 20.0 (10.0, 20.0), 20.0 (13.8, 40.0), and 20.0 (10.0, 37.5) mg/day, respectively, with a treatment duration of 28.0 (16.0, 97.5) days. The pain intensity in NRS on the day before (before) and 7 days after (after) the introduction of methadone was 6.0 (5.0, 8.0) and 4.0 (2.0, 5.0), respectively (p < 0.001). The numbers of rescue medications before and after the introduction of methadone were 4.0 (3.0, 5.0) and 3.0 (1.0, 4.0) times/day, respectively (p = 0.0015). Side effects that led to the discontinuation of methadone included nausea and dizziness in one case.
conclusionMethadone is suggested to be an effective and safe treatment option for refractory cancer pain due to pelvic floor lesions.
Indexed as
Identifiers
41073810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.